Clinical Trial Update: A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety of 12 weeks of GW856553 dosing and its effects on inflammatory markers, infarct size, and cardiac function in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• GW856553

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acute Coronary Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2017-10-27